Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123966 | 0.98 | CA2 (0.45) | CA2ALDH1A1TSHRCNR2AOC3 | |
| SCHEMBL12464629 | 0.88 | CNR2 (0.50) | TSHRCNR2KDM4E | |
| SCHEMBL24010593 | 0.85 | HTT (0.51) | ALDH1A1TSHRKDM4EMAPTHDAC3 | |
| SCHEMBL9016986 | 0.81 | TK1 (0.49) | CA2ALDH1A1TSHRCNR2AOC3 | |
| SCHEMBL8421536 | 0.81 | TK1 (0.49) | CA2ALDH1A1TSHRCNR2AOC3 | |
| SCHEMBL10276031 | 0.80 | CALM1 (0.62) | ALDH1A1TSHRKDM4E | |
| SCHEMBL9210778 | 0.80 | LMNA (0.40) | ALDH1A1TSHRCNR2NPC1RAB9A | |
| SCHEMBL11413632 | 0.79 | CNR2 (0.48) | CA2ALDH1A1TSHRCNR2AOC3 | |
| SCHEMBL9271444 | 0.78 | HDAC3 (0.45) | CA2ALDH1A1TSHRCNR2AOC3 | |
| SCHEMBL265489 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TSHRAOC3KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0564972-B1 | Peptides with N-terminal modifications having bradykinin antagonistic activity | HOECHST AG (DE) | 1999-08-11 | — | — | EP | claimed |
| US-5597803-A | POLYPEPTIDES FOR ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-01-28 | — | — | US | claimed |
| EP-4482527-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2025-05-29 | — | — | US | disclosed |
| WO-2025104230-A1 | BENZOXAZOLES AS MODULATORS OF IL-17A | SANOFI (FR) | 2025-05-22 | — | — | WO | disclosed |
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4482527-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-01-01 | — | — | EP | disclosed |
| CN-119136836-A | Cytotoxic targeting chimeras for C-C chemokine receptor 2 expressing cells | 葛兰素史克知识产权发展有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023161874-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| US-20210371387-A1 | GAS TREATING SOLUTIONS CONTAINING IMIDAZOLE-AMINE COMPOUNDS AND METHODS OF MAKING THE SAME | UNITED STATES DEPARTMENT OF ENERGY | 2021-12-02 | — | — | US | disclosed |
| EP-3280418-B1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| US-20100324259-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2073850-B1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-7799339-B2 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2073850-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | Intezyne Technologies Incorporated (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| WO-2008134731-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1287006-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2007-10-24 | — | — | EP | disclosed |
| EP-0564972-B1 | Peptides with N-terminal modifications having bradykinin antagonistic activity | HOECHST AG (DE) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371387-A1 | GAS TREATING SOLUTIONS CONTAINING IMIDAZOLE-AMINE COMPOUNDS AND METHODS OF MAKING THE SAME | NISCH, INMT, GMPS | CA2 1369/4885ALDH1A1 2482/4885TSHR 3476/4885 |
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | CCR2, CCRL2, CCR5 | CA2 3054/4885ALDH1A1 4658/4885TSHR 1581/4885 |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | CA2 1144/4885ALDH1A1 62/4885TSHR 549/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | CA2 1865/4885ALDH1A1 3966/4885TSHR 4361/4885 |
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | IL17A, IL2, IL36G | CA2 4564/4885ALDH1A1 449/4885TSHR 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.